Researchers at the University of California, Davis have developed new methods to differentiate different causes of stroke, including the first blood test that will allow clinicians to distinguish between ischemic stroke and intracerebral hemorrhage.
Clinicians diagnose stroke based on patient history, neurological exams and brain imaging. This can be difficult and distinguishing ischemic stroke from hemorrhage can be challenging when imaging is unavailable in the acute setting.
Blood transcriptomes have provided insights into the immune response following human stroke and show promise as diagnostic biomarkers. Furthermore, in the context of stroke, the importance of alternative splicing—which is the process whereby exons from a single gene are included or excluded in the final mRNA transcript—is supported by increasing evidence implicating alternative splicing in the pathogenesis of many diseases.
Using RNA sequencing, researchers at the University of California, Davis have performed the first studies examining whether alternative splicing can lead to improved biomarkers for stroke etiology. These studies have led to the development of improved methods for differentiating the different etiologies of stroke, including cardioembolic ischemic stroke, large vessel ischemic stroke, lacunar ischemic stroke, and intracerebral hemorrhage. This method is especially important, as it provides, for the first time, a blood biomarker-based method to explicitly differentiate ischemic stroke from hemorrhage.
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 11,525,161 | 12/13/2022 | 2015-533 |
stroke, diagnostic, ischemic, intracerebral hemorrhage, blood, mRNA, transcriptome, profiling